³í¹®) Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial ¿¬¼¼¾Ïº´¿ø Æó¾Ï¼¾ÅÍ Á¶º´Ã¶ ±³¼ö(»çÁø) ¿¬±¸ÆÀ